Dr. Reddy's Laboratories Limited (RDY) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Drug Manufacturers - Specialty & Generic Branche. Der Hauptsitz des Unternehmens ist in Hyderabad, India. Der aktuelle CEO ist Erez Israeli.
RDY hat IPO-Datum 2001-04-11, 27,048 Vollzeitbeschäftigte, gelistet an der NYSE, eine Marktkapitalisierung von $10.93B.
Dr. Reddy's Laboratories Limited is an integrated pharmaceutical company headquartered in Hyderabad, India, operating globally across multiple therapeutic areas including gastroenterology, cardiology, diabetes, dermatology, oncology, and respiratory medicine. The company operates through four primary segments: Global Generics, which manufactures prescription and over-the-counter finished pharmaceuticals and biologics; Pharmaceutical Services and Active Ingredients, which produces active pharmaceutical ingredients, intermediates, and contract research services; Proprietary Products, focused on differentiated formulation development; and Others, dedicated to oncology and inflammation therapies. With a strong presence in generic and branded pharmaceuticals worldwide, Dr. Reddy's has established strategic partnerships, including a collaboration with Curis, Inc. for immuno-oncology and precision oncology development. Founded in 1984, the company continues to expand its portfolio across developed and emerging markets.
